Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor

Maiko Asakura, Kazuhiro Ikegame, Satoshi Yoshihara, Shuichi Taniguchi, Takehiko Mori, Tetsuya Etoh, Akiyoshi Takami, Takashi Yoshida, Takahiro Fukuda, Kazuo Hatanaka, Heiwa Kanamori, Toshiaki Yujiri, Yoshiko Atsuta, Hisashi Sakamaki, Ritsuro Suzuki, Hiroyasu Ogawa

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Foscarnet is an active agent against cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation (HSCT), as well as ganciclovir. We investigated the usefulness of foscarnet in patients who underwent related allogeneic HSCT. Foscarnet was used in 320 patients with a median age of 45 years (range 15-72). The purpose of administration was CMV disease in 65, preemptive use in 248 and prophylaxis in 7. Totally, 194 patients had a history of prior ganciclovir treatment. The reason for foscarnet use was insufficient therapeutic effect of prior ganciclovir in 99, and adverse event including myelosuppression in 95. The response rate in symptom was 52% for the CMV disease patients. Antigenemia disappeared in 77% of the preemptive treatment and improved in 13% of the patients. No outbreak of CMV disease was recognized. The total effectiveness of therapeutic and preemptive use was significantly higher for patients without prior ganciclovir (91 vs. 76%, P = 0.001). Adverse events of grade 3 or higher were recognized in 24%, including electrolyte abnormalities in 11%, neutropenia in 8%, and thrombocytopenia in 8%. Renal damage was only observed in 3% of patients. Foscarnet was concluded to be a safe and effective anti-CMV agent and to be a suitable alternative to ganciclovir.

Original languageEnglish
Pages (from-to)351-359
Number of pages9
JournalInternational Journal of Hematology
Volume92
Issue number2
DOIs
Publication statusPublished - 2010 Sep

Fingerprint

Foscarnet
Hematopoietic Stem Cell Transplantation
Cytomegalovirus Infections
Ganciclovir
Tissue Donors
Cytomegalovirus
Therapeutic Uses
Neutropenia
Thrombocytopenia
Electrolytes
Disease Outbreaks
Kidney
Therapeutics

Keywords

  • Adverse reaction
  • Blood and marrow transplantation
  • Cytomegalovirus infection
  • Efficacy
  • Foscarnet

ASJC Scopus subject areas

  • Hematology

Cite this

Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor. / Asakura, Maiko; Ikegame, Kazuhiro; Yoshihara, Satoshi; Taniguchi, Shuichi; Mori, Takehiko; Etoh, Tetsuya; Takami, Akiyoshi; Yoshida, Takashi; Fukuda, Takahiro; Hatanaka, Kazuo; Kanamori, Heiwa; Yujiri, Toshiaki; Atsuta, Yoshiko; Sakamaki, Hisashi; Suzuki, Ritsuro; Ogawa, Hiroyasu.

In: International Journal of Hematology, Vol. 92, No. 2, 09.2010, p. 351-359.

Research output: Contribution to journalArticle

Asakura, M, Ikegame, K, Yoshihara, S, Taniguchi, S, Mori, T, Etoh, T, Takami, A, Yoshida, T, Fukuda, T, Hatanaka, K, Kanamori, H, Yujiri, T, Atsuta, Y, Sakamaki, H, Suzuki, R & Ogawa, H 2010, 'Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor', International Journal of Hematology, vol. 92, no. 2, pp. 351-359. https://doi.org/10.1007/s12185-010-0657-y
Asakura, Maiko ; Ikegame, Kazuhiro ; Yoshihara, Satoshi ; Taniguchi, Shuichi ; Mori, Takehiko ; Etoh, Tetsuya ; Takami, Akiyoshi ; Yoshida, Takashi ; Fukuda, Takahiro ; Hatanaka, Kazuo ; Kanamori, Heiwa ; Yujiri, Toshiaki ; Atsuta, Yoshiko ; Sakamaki, Hisashi ; Suzuki, Ritsuro ; Ogawa, Hiroyasu. / Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor. In: International Journal of Hematology. 2010 ; Vol. 92, No. 2. pp. 351-359.
@article{f0f4feeaad2f4f9d8e81dfc6cc37c6c7,
title = "Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor",
abstract = "Foscarnet is an active agent against cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation (HSCT), as well as ganciclovir. We investigated the usefulness of foscarnet in patients who underwent related allogeneic HSCT. Foscarnet was used in 320 patients with a median age of 45 years (range 15-72). The purpose of administration was CMV disease in 65, preemptive use in 248 and prophylaxis in 7. Totally, 194 patients had a history of prior ganciclovir treatment. The reason for foscarnet use was insufficient therapeutic effect of prior ganciclovir in 99, and adverse event including myelosuppression in 95. The response rate in symptom was 52{\%} for the CMV disease patients. Antigenemia disappeared in 77{\%} of the preemptive treatment and improved in 13{\%} of the patients. No outbreak of CMV disease was recognized. The total effectiveness of therapeutic and preemptive use was significantly higher for patients without prior ganciclovir (91 vs. 76{\%}, P = 0.001). Adverse events of grade 3 or higher were recognized in 24{\%}, including electrolyte abnormalities in 11{\%}, neutropenia in 8{\%}, and thrombocytopenia in 8{\%}. Renal damage was only observed in 3{\%} of patients. Foscarnet was concluded to be a safe and effective anti-CMV agent and to be a suitable alternative to ganciclovir.",
keywords = "Adverse reaction, Blood and marrow transplantation, Cytomegalovirus infection, Efficacy, Foscarnet",
author = "Maiko Asakura and Kazuhiro Ikegame and Satoshi Yoshihara and Shuichi Taniguchi and Takehiko Mori and Tetsuya Etoh and Akiyoshi Takami and Takashi Yoshida and Takahiro Fukuda and Kazuo Hatanaka and Heiwa Kanamori and Toshiaki Yujiri and Yoshiko Atsuta and Hisashi Sakamaki and Ritsuro Suzuki and Hiroyasu Ogawa",
year = "2010",
month = "9",
doi = "10.1007/s12185-010-0657-y",
language = "English",
volume = "92",
pages = "351--359",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor

AU - Asakura, Maiko

AU - Ikegame, Kazuhiro

AU - Yoshihara, Satoshi

AU - Taniguchi, Shuichi

AU - Mori, Takehiko

AU - Etoh, Tetsuya

AU - Takami, Akiyoshi

AU - Yoshida, Takashi

AU - Fukuda, Takahiro

AU - Hatanaka, Kazuo

AU - Kanamori, Heiwa

AU - Yujiri, Toshiaki

AU - Atsuta, Yoshiko

AU - Sakamaki, Hisashi

AU - Suzuki, Ritsuro

AU - Ogawa, Hiroyasu

PY - 2010/9

Y1 - 2010/9

N2 - Foscarnet is an active agent against cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation (HSCT), as well as ganciclovir. We investigated the usefulness of foscarnet in patients who underwent related allogeneic HSCT. Foscarnet was used in 320 patients with a median age of 45 years (range 15-72). The purpose of administration was CMV disease in 65, preemptive use in 248 and prophylaxis in 7. Totally, 194 patients had a history of prior ganciclovir treatment. The reason for foscarnet use was insufficient therapeutic effect of prior ganciclovir in 99, and adverse event including myelosuppression in 95. The response rate in symptom was 52% for the CMV disease patients. Antigenemia disappeared in 77% of the preemptive treatment and improved in 13% of the patients. No outbreak of CMV disease was recognized. The total effectiveness of therapeutic and preemptive use was significantly higher for patients without prior ganciclovir (91 vs. 76%, P = 0.001). Adverse events of grade 3 or higher were recognized in 24%, including electrolyte abnormalities in 11%, neutropenia in 8%, and thrombocytopenia in 8%. Renal damage was only observed in 3% of patients. Foscarnet was concluded to be a safe and effective anti-CMV agent and to be a suitable alternative to ganciclovir.

AB - Foscarnet is an active agent against cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation (HSCT), as well as ganciclovir. We investigated the usefulness of foscarnet in patients who underwent related allogeneic HSCT. Foscarnet was used in 320 patients with a median age of 45 years (range 15-72). The purpose of administration was CMV disease in 65, preemptive use in 248 and prophylaxis in 7. Totally, 194 patients had a history of prior ganciclovir treatment. The reason for foscarnet use was insufficient therapeutic effect of prior ganciclovir in 99, and adverse event including myelosuppression in 95. The response rate in symptom was 52% for the CMV disease patients. Antigenemia disappeared in 77% of the preemptive treatment and improved in 13% of the patients. No outbreak of CMV disease was recognized. The total effectiveness of therapeutic and preemptive use was significantly higher for patients without prior ganciclovir (91 vs. 76%, P = 0.001). Adverse events of grade 3 or higher were recognized in 24%, including electrolyte abnormalities in 11%, neutropenia in 8%, and thrombocytopenia in 8%. Renal damage was only observed in 3% of patients. Foscarnet was concluded to be a safe and effective anti-CMV agent and to be a suitable alternative to ganciclovir.

KW - Adverse reaction

KW - Blood and marrow transplantation

KW - Cytomegalovirus infection

KW - Efficacy

KW - Foscarnet

UR - http://www.scopus.com/inward/record.url?scp=77956931012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956931012&partnerID=8YFLogxK

U2 - 10.1007/s12185-010-0657-y

DO - 10.1007/s12185-010-0657-y

M3 - Article

C2 - 20694532

AN - SCOPUS:77956931012

VL - 92

SP - 351

EP - 359

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 2

ER -